Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges. Incretin‐based therapies, including the GLP‐1 receptor agonists semaglutide and liraglutide, and the dual GIP/GLP‐1 receptor agonist tirzepatide, are increasingly used to ad...
H. Bawadi, Haya Abuhijleh, Mamon Nofal et al.· Endocrinology, Diabetes & Me...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.